Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Can CAR T-cells be optimised to safely treat MM patients?

Rakesh Popat, MD, PhD, from University College London, London, UK, talks to us about the potential of applying CAR T-cell therapy to treat multiple myeloma (MM). Here, he references abstracts presented at EHA by two companies, Bluebird Bio and Nanjing Legend Biotech, who have investigated their CAR T-cell constructs in patients with relapsed MM in clinical trials and achieved impressive results, namely a 100% response rate in all patients (NCT02658929) (NCT03090659). He also talks about his team’s own CAR T-cell construct, which he hopes will be more specific and potent than other CAR T-cells and also safer due to its built in ‘safety switch.’ This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.